Welcome to our dedicated page for Forte Biosciences news (Ticker: FBRX), a resource for investors and traders seeking the latest updates and insights on Forte Biosciences stock.
Forte Biosciences, Inc. reports developments tied to FB102, its proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases. Recurring updates cover clinical development in celiac disease, non-segmental vitiligo and alopecia areata, including regulatory designations such as Fast Track status in celiac disease.
Company news also includes quarterly and annual financial results, research and development spending tied to FB102, public financing activity, investor meeting participation and Nasdaq-required disclosures for equity inducement awards under its 2020 Inducement Equity Incentive Plan.
argenx (Euronext & Nasdaq: ARGX) announced completion of its acquisition of Forte Biosciences (Nasdaq: FBRX), adding FB102, a first-in-class anti-CD122 antibody, to its immunology pipeline. FB102 has clinical proof-of-concept in vitiligo and celiac disease and is described as having potential across multiple autoimmune indications.
According to argenx, FB102 complements existing antibody programs such as efgartigimod, empasiprubart, adimanebart and ARGX-121 by targeting pathogenic T-cell and NK-cell activity. argenx completed a cash tender offer through a subsidiary at $77.00 per Forte share. As of expiration, 19,894,879 shares were validly tendered and not withdrawn, which, together with shares already owned by argenx and affiliates, represented approximately 87.13% of Forte’s outstanding common stock. These shares were accepted for payment.
Following the tender offer, argenx completed a merger of its wholly owned subsidiary into Forte. All remaining Forte shares were converted into the right to receive $77.00 in cash per share, subject to tax withholding. Forte became a wholly owned subsidiary of argenx, and Forte’s common stock will cease trading on the Nasdaq Capital Market.
argenx (Euronext & Nasdaq: ARGX) has launched a cash tender offer, through its wholly owned subsidiary Avena Merger Sub, to acquire all outstanding shares of Forte Biosciences (Nasdaq: FBRX) at $77.00 per share, net to the seller in cash, without interest and subject to withholding taxes.
The offer is made under a July 26, 2026 Merger Agreement among argenx, the Purchaser and Forte. Following acceptance of shares and satisfaction or waiver of conditions, Purchaser will merge into Forte under DGCL Section 251(h), making Forte a wholly owned subsidiary of argenx, with remaining shares also converted into the right to receive $77.00 in cash per share.
The offer expires at one minute after 11:59 p.m. Eastern Time on August 26, 2026, unless extended or earlier terminated. Closing is subject to a Minimum Condition (more than 50% of outstanding shares, including those already owned by Purchaser and its affiliates, being validly tendered and not withdrawn) and expiration or termination of the Hart-Scott-Rodino antitrust waiting period, among other conditions. The offer is not subject to a financing condition. Forte’s Board has filed a Schedule 14D-9 with the SEC recommending that stockholders accept the offer and tender their shares. Offer materials and the Forte board’s recommendation are available via the SEC and company investor relations websites.
Forte Biosciences (NASDAQ:FBRX) reported positive phase 1b results for FB102 in vitiligo. In the efficacy-evaluable population, FB102 achieved a 29.6% mean FVASI improvement at week 24 versus 7.9% on placebo (p=0.020). Subjects with baseline FVASI ≥0.75 showed 43.2% mean improvement vs 0.5% on placebo (p=0.006), with FVASI50 in 58.8% and FVASI75 in 23.5% of FB102-treated patients. Overall, 84% of FB102-treated subjects improved and none worsened by week 24, while 27% of placebo subjects worsened. All adverse events were mild or moderate, and FB102 compared favorably to placebo.
Forte Biosciences (NASDAQ:FBRX) granted equity inducement awards under Nasdaq Listing Rule 5635(c)(4) to a new non-executive employee. The grant includes options to purchase 50,000 shares and 50,000 restricted stock units, both vesting over four years, subject to continuous employment.
Forte Biosciences (NASDAQ:FBRX) reported Q1 2026 results and announced that FB102 received FDA Fast Track designation for celiac disease. FB102 phase 2 celiac topline data are expected in 2026, with phase 1b vitiligo readout shortly and alopecia areata data in 2026.
Q1 2026 research and development expenses were $20.5 million, general and administrative expenses were $2.0 million, and net loss per share was $(1.24). Forte ended the quarter with $58.2 million in cash and later raised $172.5 million gross in an April 2026 equity offering.
Forte Biosciences (Nasdaq: FBRX) priced a public offering of 5,709,936 common shares at $26.27 per share, with underwriters granted a 30-day option for up to 856,490 additional shares. Gross proceeds are expected to be approximately $150 million.
The offering is expected to close on or about April 10, 2026. Forte said net proceeds will fund working capital, clinical development of its product candidate, and other research activities.
Forte Biosciences (Nasdaq: FBRX) announced a proposed underwritten public offering of its common stock on April 8, 2026. Forte said it expects to grant underwriters a 30-day option to buy up to an additional 15% of the offered shares. All shares are being offered by the company and proceeds are intended for working capital, clinical development of its product candidate, and general corporate purposes. The offering is subject to market conditions and will be made pursuant to an effective Form S-3 registration statement; a preliminary prospectus supplement will be filed with the SEC.
Forte Biosciences (NASDAQ: FBRX) reported full-year 2025 results and a clinical update for FB102. R&D spending rose to $58.2M driven by Phase 2 celiac and multiple Phase 1b trials. Cash and equivalents were $77.0M at year-end with 12.9M shares outstanding.
The company expects multiple FB102 topline readouts in 2026, including Phase 2 celiac results and Phase 1b readouts in vitiligo and alopecia areata.
Forte Biosciences (NASDAQ: FBRX) announced inducement equity option awards totaling 25,000 shares to new non-executive employees, granted under the company’s 2020 Inducement Equity Incentive Plan. The options vest over four years: 25% after one year and the remaining 75% monthly over the next 36 months, subject to continuous employment.
The grants were approved by the Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4) as material inducements for new hires.
Forte Biosciences (NASDAQ: FBRX) announced inducement equity awards for new non‑executive employees under Nasdaq Listing Rule 5635(c)(4). The company granted options to purchase an aggregate 100,000 shares of common stock under the 2020 Inducement Equity Incentive Plan.
The options vest over four years: 25% after one year and the remaining 75% in approximately equal monthly installments over the next 36 months, subject to continued employment and the related award agreements.